Galapagos Raises $27.1M in Share Placement | GenomeWeb

NEW YORK (GenomeWeb News) – Galapagos, the Belgian drug development and drug screening services firm, has raised €18.2 million ($27.1 million) through the placement of 2,125,925 new ordinary shares at a price of €8.55 per share.

The shares are being placed with unnamed international institutional investors. Delivery of the shares is expected to take place on Oct. 21.

Galapagos plans to use the funds to support clinical development of drug candidates, including a phase II study of a rheumatoid arthritis drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.